Cargando…

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.

We examined the effects of misonidazole (MISO) and recombinant human tumour necrosis factor (rh-TNF) on tumour blood flow in mice given hyperthermic treatments. MISO (500 mg kg-1) or rh-TNF (6 x 10(4) unit kg-1) was administered intraperitoneally (i.p.) prior to hyperthermia to nude mice bearing a x...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujimoto, S., Kobayashi, K., Takahashi, M., Konno, C., Kokubun, M., Ohta, M., Shrestha, R. D., Kiuchi, S.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1992
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977348/ https://www.ncbi.nlm.nih.gov/pubmed/1733439

Ejemplares similares

The penetration of misonidazole into spontaneous canine tumours.
por: White, R. A., et al.
Publicado: (1979)

Effect of local hyperthermia on the acute toxicity of misonidazole in mice.
por: Overgaard, J.
Publicado: (1979)

The quantitative response of human tumours to radiation and misonidazole.
por: Ash, D. V., et al.
Publicado: (1979)

Distribution of misonidazole in human tumours and normal tissues.
por: Ash, D. V., et al.
Publicado: (1979)

The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing mice.
por: MacManus, M. P., et al.
Publicado: (1989)

Influence of misonidazole on the incidence of radiation-induced intestinal tumours in mice.
por: Rostom, A. Y., et al.
Publicado: (1978)

Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.
por: Durand, R. E., et al.
Publicado: (1987)

Is tumour radiosensitization by misonidazole a general phenomenon?
por: Denekamp, J., et al.
Publicado: (1980)

Interactions between misonidazole and hyperthermia in EMT6 spheroids.
por: Morgan, J. E., et al.
Publicado: (1981)

Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
por: Law, M. P., et al.
Publicado: (1981)

Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse.
por: Honess, D. J., et al.
Publicado: (1980)

Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.
por: Pedersen, J. E., et al.
Publicado: (1979)

Misonidazole reduces blood flow in two experimental murine tumours.
por: Murray, J. C., et al.
Publicado: (1988)

Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
por: Twentyman, P. R.
Publicado: (1981)

Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
por: Rojas, A., et al.
Publicado: (1983)

Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
por: Horsman, M. R., et al.
Publicado: (1984)

Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
por: Siemann, D. W.
Publicado: (1982)

Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.
por: Brown, N. J., et al.
Publicado: (1997)

Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
por: Brown, J. M., et al.
Publicado: (1982)

Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
por: Lee, F. Y., et al.
Publicado: (1985)

In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
por: Siemann, D. W., et al.
Publicado: (1984)

A new approach to the use of misonidazole as a radiosensitizer of hypoxic tumour cells.
por: Abratt, R. P.
Publicado: (1982)

The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.
por: McNally, N. J.
Publicado: (1982)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.
por: Walton, M. I., et al.
Publicado: (1989)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Bleomycin and misonidazole cytotoxicity.
por: Korbelik, M., et al.
Publicado: (1985)

Trafficking of ‘immune’ CD4(+)/CD8(+) T-lymphocytes into the RENCA tumour microcirculation in vivo in mice
por: Ali, S A, et al.
Publicado: (2000)

Local tumour hyperthermia as immunotherapy for metastatic cancer
por: Toraya-Brown, Seiko, et al.
Publicado: (2014)

Peripheral electrophysiological parameters in mice treated with misonidazole.
por: Von Burg, R., et al.
Publicado: (1979)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Vascular damage and delayed cell death in tumours after hyperthermia.
por: Song, C. W., et al.
Publicado: (1980)

Synergism of chlorpromazine and hyperthermia in two mouse solid tumours.
por: George, K. C., et al.
Publicado: (1982)

Ultrasound microbubble potentiated enhancement of hyperthermia-effect in tumours
por: Sharma, Deepa, et al.
Publicado: (2019)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.
por: Trentin, L., et al.
Publicado: (1995)

In vitro metabolism of misonidazole.
por: Josephy, P. D., et al.
Publicado: (1981)

Response of EMT6 multicellular tumour spheroids to hyperthermia and cytotoxic drugs.
por: Morgan, J. E., et al.
Publicado: (1981)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Relationship between tumour cell morphology, gap junctions and susceptibility to cytolysis by tumour necrosis factor.
por: Matthews, N., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_97nt1j75jotrtqtdhv53toqnoq